Technology-enabled insights into SLC transporters in MAFLD: redefining the multi-hit pathogenesis and therapeutic landscape

Chen H, Zhou Y, Hao H, Xiong J. Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies. Chin J Nat Med. 2024;22:724–45.

CAS 
PubMed 

Google Scholar 

Cartland SP, Harith HH, Genner SW, Dang L, Cogger VC, Vellozzi M, et al. Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice. Sci Rep. 2017;7:1898.

Article 
PubMed 
PubMed Central 

Google Scholar 

Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119:1787–98.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Carnagarin R, Tan K, Adams L, Matthews VB, Kiuchi MG, Marisol Lugo Gavidia L, et al. Metabolic-dysfunction-associated fatty liver disease (MAFLD) is a condition associated with heightened sympathetic activation. Int J Mol Sci. 2021;22:4241.

Feng G, Targher G, Byrne CD, Yilmaz Y, Wai-Sun Wong V, Adithya Lesmana CR, et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2025;7:101271.

Article 
PubMed 

Google Scholar 

Fan H, Wang R, Wen B, Xiong J. Biomarkers and potential therapeutic targets driving progression of non-alcoholic steatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis. Front Immunol. 2024;15:1502263.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Xu Q, Feng M, Ren Y, Liu X, Gao H, Li Z, et al. From NAFLD to HCC: advances in noninvasive diagnosis. Biomed Pharmacother. 2023;165:115028.

Article 
PubMed 

Google Scholar 

Esler WP, Bence KK. Metabolic targets in nonalcoholic fatty liver disease. Cell Mol Gastroenterol Hepatol. 2019;8:247–67.

Article 
…